Nigerian Pharmaceutical Sector Faces Financial Strain Amid Rising Interest Rates
Nigerian pharmaceutical companies have increasingly turned to short-term bank loans to finance their operations, expansion efforts, and working capital. However, this funding model is currently under severe pressure as soaring interest rates and currency fluctuations complicate debt sustainability. By the second quarter of 2026, industry experts expect substantial structural changes as companies begin to restructure their balance sheets in a bid to mitigate high debt exposure.
Cost of Capital Remains a Major Challenge
At the heart of this transformation is the escalating cost of capital. The Central Bank of Nigeria’s monetary policy rate, currently set at 26.5%, remains a significant burden for manufacturers. Commercial lending rates often surpass 30%, a figure many in the pharmaceutical sector deem unsustainable due to lengthy production cycles and the high cost of imported inputs.
High Interest Rates Limit Growth Potential
According to Patrick Ajah, managing director of May & Baker Nigeria, loan rates as high as 33% make it nearly impossible for manufacturers to achieve even a break-even point, particularly in capital-intensive sectors like active pharmaceutical ingredient (API) production. As debt becomes a liability rather than a growth enabler, companies increasingly allocate a large portion of their cash flows to debt servicing, reducing available funds for production, procurement, and expansion.
Currency Fluctuations and Input Costs Intensify Financial Pressures
The situation is exacerbated by rising input costs, which heavily depends on imported materials. Industry estimates indicate over 70% of pharmaceutical raw materials in Nigeria are sourced from abroad, exposing manufacturers to unfavorable currency shifts. A decline in the naira raises the costs of pharmaceutical ingredients, necessitating greater working capital to maintain production levels.
Market Instability Drives Up Operational Costs
Global market volatility has further added to these pressures. Key input prices, such as paracetamol, have surged recently due to supply chain disruptions and geopolitical tensions. For local manufacturers, this translates into heightened operational costs, which are compounded by the escalating expense of financing these inputs. As a result, cash flow is increasingly strained, with companies facing growing costs to procure raw materials while also managing debt repayment obligations.
Shift Toward Restructuring Financing Models
In response to these challenges, restructuring is gaining traction among companies in the sector. This process commonly involves revising financing strategies to alleviate cash flow pressures, which may entail extending loan terms, renegotiating interest rates, or converting short-term debt into long-term obligations. Some companies have already initiated these steps. For instance, Fidson Healthcare raised around N21 billion in early 2026 through a rights issue, aiming to fortify its capital structure and reduce reliance on short-term loans.
Industry Evolution and Future Outlook
As pharmaceutical companies reassess their financing strategies, the competitive landscape is also shifting. The exit of multinationals like GlaxoSmithKline and Sanofi has created a supply gap, presenting an urgent need for local manufacturers to ramp up production. However, these enhancements typically require substantial capital investments, which short-term loans with high-interest rates cannot efficiently support.
Equity financing emerges as a viable option, despite its potential for dilution, offering a more stable funding alternative. Unlike debt, equity does not impose immediate repayment obligations, allowing companies to invest in capacity and mitigate short-term shocks. Meanwhile, policy initiatives aimed at boosting local drug production are encouraging further investments in domestic manufacturing, even amid a tax cut that exempts numerous pharmaceutical raw materials from VAT.
Overall, the shift toward restructuring marks the beginning of a new financial approach for Nigerian pharmaceutical firms. Companies that replace high-cost short-term debt with equity or extend loan terms can enhance their operational flexibility and better address the gaps left by multinational exits. While early movers like Fidson and Neimeth have taken proactive steps to strengthen their balance sheets, other firms are still grappling with the challenges posed by rising input costs and exchange rate volatility. The necessity for restructuring continues to grow as high borrowing costs and import dependencies loom large over the sector.
